螺内酯、依那普利、卡维地洛联合治疗慢性收缩性心力衰竭临床疗效观察被引量：4

Clinical curative effect observation of combined therapy with spironolactone,enalapril and carvedilol for chronic systolic heart failure

下载PDF

导出

摘要目的:探讨螺内酯、依那普利、卡维地洛联合治疗慢性收缩性心力衰竭的疗效。方法:收治慢性收缩性心力衰竭患者60例,随机分为对照组和治疗组各30例,对照组采用常规治疗,治疗组采用螺内酯+依那普利+卡维地洛治疗,比较两组的治疗效果。结果:治疗组总有效率及心功能指标改善均优于对照组,差异有统计学意义(P<0.05)。结论:螺内酯、依那普利、卡维地洛联合治疗慢性收缩性心力衰竭的疗效显著。 Objective:To explore the clinical curative effect of combined therapy with spironolactone,enalapril and carvedilol forchronic systolic heart failure.Methods:60 patients with chronic systolic heart failure were selected.They were randomly dividedinto the control group and the treatment group with 30 cases in each group.Patients in the control group were given conventionaltreatment,while patients in the treatment group were given combined therapy with spironolactone,enalapril and carvedilol,then wecompared the treatment effect of two groups.Results:The total effective rate and the improvement of cardiac function in thetreatment group were better than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:The clinical curative effect of combined therapy with spironolactone,enalapril and carvedilol for chronic systolic heart failure wassignificant.

作者朱彩玲 Zhu Cailing(The Center Health Hospital of Tewulike Town,Heshuo County,Ba State,Xinjiang 841200)

机构地区新疆巴州和硕县特吾里克镇中心卫生医院

出处《中国社区医师》 2016年第13期53-53,55,共2页 Chinese Community Doctors

关键词螺内酯依那普利卡维地洛慢性收缩性心力衰竭 Spironolactone Enalapril Carvedilol Chronic systolic heart failure

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1王吉云,胡大一,贾三庆.重新评价醛固酮在心血管疾病中的作用[J].中国医刊,2002,37(4):22-23. 被引量：18
2杨田,沈萍,赵仙先.卡维地洛药理作用的研究进展[J].心血管病学进展,2003,24(2):110-113. 被引量：50

二级参考文献31

1[11]Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228 [J]. Biochem Pharmacol ,2001,61 (2): 155-164.
2[12]Noguchi N, Nishino K,Niki E. Antioxidant action of the antihypertensive drug,carvedilol, against lipid peroxidation [J]. Biochem Pharmacol, 2000, 59 ( 9 ):1069-1076.
3[13]Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis :protective role of carvedilol [J]. J Am Coll Cardilo,2001 ,36( 7 ) :2081-2089.
4[14]Romeo F,LiM D,Shi M ,et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells:modulation of Fas/Fsa ligand and caspase-3 pathway [ J ]. Cardiovasc Res, 2000,45 ( 3 ) :788-794.
5[15]Cao F,Chen J,Lopez BL,et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model [ J ]. Eur J Pharmacol,2000,406( 1 ) :109-116.
6[16]Wei S.Chow LT,Sanderson JE,et al. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction[J]. J Am Coll Cardiol.2000,36( 1 ) :276-281.
7[17]Ohta Y, Watanabe K, Nakazawa M,et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart[ J ]. J Cardiovasc Pharmacol,2000,36 ( suppl 2 ) 19-23.
8[18]Savitz SI, Erhardt JA, Anhtony JV, et al. The novel β-bolcker, carvedilol, provides neuroprotection in transient focal stroke[J]. J Cereb Blood Flow Metab,2000,20(8) :1197-1204.
9[19]Karle CA, Kreye VA,Thomas D, et al. Antarrhythmic drug carvedilol inhibits HERG potassium channels [ J ]. Cardiovasc Res,2001,49 ( 2 ): 361-370.
10[20]Takusagawa M, Komori S, Matsumura K, et al. The inhibitory effects of carvedilol against arhytmias induced by coronary by coronary reperfusion in aneothetized rats [J]. J Cardiovasc Pharmacol Ther, 2000, 5 ( 2 ): 105 - 112.